Acthar + Depo Medrol for Rheumatoid Arthritis

"Acthar Injectable Product can be used to treat scalp structure, multiple sclerosis, and ulcerative colitis."

"According to the latest information found on clinicaltrials.gov, this particular trial is not currently looking for new participants. This study was originally posted on October 2nd, 2018 and was last edited on July 18th, 2022. Although this research is not presently looking for patients, there are 923 other studies that are."

"The primary outcome of this study will be the degree of inflammation after a short-term treatment, as measured by a pathologist during histological assessment. This will be done over a period of five days after the first injection. Secondary outcomes include the number of tender and swollen joints after long-term treatment, as measured by a clinician while palpating 28 specified joints. Another secondary outcome is the initial erythrocyte sedimentation rate (ESR) present in blood (in mm/h). This is defined as the Westergren method, which requires collecting 2 ml of venous blood into a tube containing 0.5 ml of"

"Currently, there are 160 clinical trials underway for the Acthar Injectable Product. Of those, 42 are in the third and final stage. Although the majority of trials for this treatment are taking place in Duarte, California, there are a total of 6826 locations running trials for the Acthar Injectable Product."

"Acthar Injectable Product's safety is estimated to be a 3. This is due to the product being in Phase 3 trials, which suggests that while there is data supporting its efficacy, there is also data supporting its safety from multiple rounds of testing."

"This clinical trial is no longer recruiting patients. The study was first posted on October 2nd, 2018 and was last updated on July 18th, 2022. There are currently 763 other trials for rheumatoid arthritis and 160 trials for Acthar Injectable Product that are actively enrolling participants."